The Food and Drug Administration (FDA) has approved Somatuline Depot (lanreotide; Ipsen Biopharmaceuticals) injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ...
The redesigned syringe includes a needle shield removal system and more stable plunger and thermoform tray with recessed areas designed to help prevent accidental plunger depression. The Food and Drug ...
Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a ...
Please provide your email address to receive an email when new articles are posted on . In the LOCKCYST I clinical trial, a low dose of Somatuline Depot injection for the treatment of polycystic liver ...
Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results